The One Click Group

The One Click Group
Health Advocacy

RSS Feed Follow OneClickGroup on Twitter

Dr Iain Stephenson
Found Guilty of Vaccine
Research Fraud
The One Click Group

Mobilising ME/CFS Charities
To Smash Flawed
PACE Trial Results
Lara, Health Advocate

UK Public Health
In Dire Straits
Dr Dick van Steenis MBBS

Lies Damned Lies
Swine Flu
Statistics Exposed
By Lara

Vaccination Graphs
The Awful Stats In Action
Raymond Obomsawin Ph.D

Issues In Immunization
Theory And Practice
Raymond Obomsawin Ph.D

March 2010

One Click
Of Information
UK Police Harassment
In The Internet Era

Barbara Loe Fisher
NVIC Conference
Style, Gonads
Brass Ovaries
By Jane Bryant

New Journalism
Status Quo
By Jane Bryant
NVIC Conference

How The
Judicial Review
NICE Guidelines
Was Lost
Jane Bryant
The One Click Group

Vaccines Propaganda
David Salisbury
Public Relations

David Southall
"A Very
Dangerous Doctor"
Panorama swims
with sharks
Lisa Blakemore Brown

Dr David Salisbury
Never Mind Me,
I'm Basil Fawlty!

David Salisbury
Vaccine Litigation

The Politics
And Commerce
Of Autism
By Lisa Blakemore Brown

Vaccine/Autism Case
Mitochondrial Disfunction
ME/CFS Patients

The Consensus Report
Family Law Reform

Canadian Definition of ME-CFS

The Weird World of Wikipedia
By Martin J. Walker

Click here to email us with any thoughts or opinions you wish to share about the website.


News Archives 4841-4860
Number Title Post Date
4841 Is a 14% Chantix success rate worth risking death? 15/06/2011 13:47:18
4842 The Pentagon Papers Unredacted 15/06/2011 13:48:56
4843 Another study says mobile usage ups fatal cancer risk 15/06/2011 13:52:56
4844 WSJ and Al-Jazeera Lure Whistleblowers With False Promises of Anonymity 15/06/2011 13:54:41
4845 Activists cry foul over FBI probe 15/06/2011 13:57:55
4846 Tango down for lulz 16/06/2011 11:17:54
4847 The Julian Assange Vanity Project 16/06/2011 11:19:12
4848 WikiLeaks spokesman: Guardian, NYT wanted to rush war logs 16/06/2011 11:21:45
4849 David House Takes The Fith: Statement on the WikiLeaks Grand Jury 16/06/2011 11:23:16
4850 Official record reveals truth behind Adrian Lamo's Asperger incident 16/06/2011 11:24:48
4851 4,000 goats die in China after vaccination 16/06/2011 11:25:58
4852 Yellow Fever Vaccine Risky for MS Patients 16/06/2011 11:27:46
4853 Pfizer, BI Inhaler May Raise Risk Of Early Death 16/06/2011 11:29:20
4854 Confidential Expert Witness Report Documents Psychiatrists Corrupt Practices 16/06/2011 11:30:13
4855 Subject to approval: An investigation into clinical drug trials abroad 16/06/2011 11:32:25
4856 MPs want talks on the Digital Economy Act axe 17/06/2011 10:45:57
4857 WikiLeaks: Government spying on Julian Assange during house arrest 17/06/2011 10:47:38
4858 How 1 point becomes 15 in bogus UK medicals 17/06/2011 11:08:37
4859 Rotavirus Vaccine Linked to Life-Threatening Bowel Disorder 17/06/2011 11:10:00
4860 Parents blame infant's death on polio drops 17/06/2011 11:10:55

[Previous] [Next]

Pfizer, BI Inhaler May Raise Risk Of Early Death
Share |

Pfizer, BI Inhaler May Raise Risk Of Early Death

spirivaThe blockbuster inhaled lung medication Spiriva, which is sold by Pfizer and Boehringer Ingelheim, may raise the risk of an early death, according to a new review of clinical studies. When administered in mist form, the drug was associated with a 52 percent increase in mortality risk, compared with patients given a placebo, according to the review of clinical trials involving more than 6,500 patients published in the British Medical Journal.

The findings appear 18 months after the FDA completed a two-year review of the drug and decided Spiriva did not increase the risk of heart attack and stroke (read here). Earlier studies had suggested a potential risk. Patients who took Spiriva or an older, generic drug had a 58 percent higher risk of heart attack, stroke and death from heart disease, according to a meta-analysis published in 2008 in the Journal of the American Medical Association (see here).

Spiriva is a long-acting treatment for chronic obstructive pulmonary disease and is sold as a mist that is delivered with the Respimat inhaler, and as a powder, which is delivered with a Handihaler device. The mist inhaler is available in 55 countries, although it is not yet approved yet in the US. For its part, Boehringer is conducting a study of more than 17,000 patients comparing Spiriva Respimat and Spiriva Handihaler to verify safety and efficacy.

Those results are due in early 2014, but until the results are released, “the indirect evidence that is currently available suggests that the Handihaler is a safer bet than the Respimat,” Christopher Cates, a senior clinical research fellow at St. George’s University of London, wrote in an accompanying editorial.

UPDATE: In response, Boehringer issued this response: “Boehringer Ingelheim and Pfizer disagree with the authors’ conclusion that this meta-analysis proves a risk for tiotropium delivered via the soft mist inhaler Respimat in COPD patients. Efficacy and safety of Spiriva Respimat has been established by a stand alone clinical development program and is fully described in the approved product label.

“The authors’ conclusions are not based on new clinical evidence. Data from the five clinical trials used in this meta-analysis are already publicly available, have been submitted to the regulatory agencies and are appropriately reflected in the Spiriva Respimat label. When analyzing the clinical data, Boehringer Ingelheim and Pfizer – unlike the authors of the publication – have access to detailed patient level data. A thorough analysis of these data revealed a statistically non-significant, numerical imbalance in number of fatal events with Spiriva Respimat. Mortality rates observed in the analyzed studies were within the range of other large COPD trials. These data have been submitted to regulatory authorities worldwide and findings are fully described in the approved product label.”

UK Web Hosting by Thu, June 16th, 2011. 11:29 am